TRUQAP + fulvestrant keeps cancer from growing or spreading for more than 2X longer than fulvestrant alone
TRUQAP + fulvestrant is proven to give people with HR+/HER2- mBC with abnormal PIK3CA, AKT1, and/or PTEN genes more than twice as long without their cancer growing or spreading compared with the hormone therapy fulvestrant alone. This is called progression-free survival.*
MORE
THAN
2X
LONGER WITHOUT TUMOR GROWTH
TRUQAP + fulvestrant delivered a median of
7.3 months vs 3.1 months with fulvestrant alone—
a difference of 4.2 months.†
Results may vary.
The trial showed no significant difference in how long patients lived between treatment groups.
*PFS is a measure of how long a treatment keeps cancer from growing or spreading.
†Median PFS is the time point at which half the patients have experienced disease progression. Median is the middle number in a group of numbers listed from lowest to highest.
Progression-free survival is the amount of time that your cancer doesn’t grow or spread while you’re on therapy.
Not actual patients.
How TRUQAP was studied
TRUQAP was studied in a global clinical trial that included 708 people with HR+/HER2- metastatic breast cancer with or without abnormal PIK3CA, AKT1, and/or PTEN genes whose cancer grew or spread on hormone therapy.
The study group included:
- Pre/peri- and postmenopausal women, and men‡
- Average age of 58
- All patients had received prior hormone (aromatase inhibitor) therapy for their breast cancer
- 70% of people in the study had been previously treated with a CDK4/6 inhibitor
FDA approval was based on results in 289 patients with abnormal PIK3CA, AKT1, and/or PTEN genes (155 patients treated with TRUQAP + fulvestrant vs 134 patients treated with placebo + fulvestrant).
‡Pre-/perimenopausal women were also given a luteinizing hormone-releasing hormone agonist.
Two of the study’s main goals were:
Determine the safety of TRUQAP + fulvestrant
See how well the combination could keep cancer from growing or spreading vs fulvestrant alone
Not an actual patient.
Not an actual patient.
For people with HR+/HER2– metastatic breast cancer with abnormal PIK3CA, AKT1, and/or PTEN genes following progression on or after hormone therapy
TRUQAP + fulvestrant keeps cancer from growing or spreading for more than 2X longer vs fulvestrant alone
How to take TRUQAP
Taking TRUQAPLearn about TRUQAP side effects
SafetyAKT1=serine/threonine protein kinase 1; CDK4/6=cyclin-dependent kinase 4/6; HER2-=human epidermal growth factor receptor 2 negative; HR+=hormone receptor positive; mBC=metastatic breast cancer; PIK3CA=phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha; PTEN=phosphatase and tensin homolog.
Important Safety Information about TRUQAP® (capivasertib) tablets
Expand
Important Safety Information about TRUQAP® (capivasertib) tablets
Do not take TRUQAP if you have had a severe allergic reaction to TRUQAP or are allergic to any of the ingredients of TRUQAP.
Before you take TRUQAP, tell your healthcare provider about all your medical conditions, including if you:
- have a history of high levels of sugar in your blood or diabetes
- have a history of rash or other skin disorders
- have liver problems
- have any current infection
- are pregnant or plan to become pregnant. TRUQAP can harm your unborn baby
Females who are able to become pregnant:
- Your healthcare provider will check to see if you are pregnant before you start treatment with TRUQAP
- You should use effective birth control during treatment with TRUQAP and for 1 month after the last dose. Talk to your healthcare provider about birth control methods that may be right for you during this time
- If you become pregnant or think you are pregnant, tell your healthcare provider right away
Males with female partners who are able to become pregnant should use effective birth control during your treatment with TRUQAP and for 4 months after the last dose. If your female partner becomes pregnant, tell your healthcare provider right away.
- are breastfeeding or plan to breastfeed. Do not breastfeed during treatment with TRUQAP. Talk to your healthcare provider about the best way to feed your baby during treatment with TRUQAP
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. TRUQAP may affect the way other medicines work, and other medicines may affect how TRUQAP works. Know the medicines you take. Keep a list of them to show your healthcare provider or pharmacist when you get a new medicine.
How should I take TRUQAP?
- Take TRUQAP exactly as your healthcare provider tells you
- Do not change your dose or stop taking TRUQAP unless your healthcare provider tells you
- Take TRUQAP 2 times each day (about 12 hours apart) in the morning and evening, at about the same times each day
- Take TRUQAP for 4 days in a row, followed by 3 days not taking TRUQAP each week
- Take TRUQAP with or without food
- Swallow TRUQAP tablets whole with water. Do not chew, crush, or split the tablets. Do not take any tablets that are broken, cracked, or that look damaged
- If you miss a dose of TRUQAP, you may still take it within 4 hours from the time you usually take it. If it has been more than 4 hours after you usually take your dose, skip that dose. Take the next dose at your usual time. Do not take 2 doses to make up for a missed dose
- If you vomit after taking a dose of TRUQAP, do not take an additional dose. Take your next dose at your usual time
- For women who have not reached menopause or are just starting menopause, your healthcare provider will prescribe a medicine called a luteinizing hormone-releasing hormone (LHRH) agonist to take with TRUQAP and fulvestrant. For men, your healthcare provider may prescribe a LHRH agonist to take with TRUQAP and fulvestrant
What are the possible side effects of TRUQAP?
TRUQAP may cause severe side effects, including:
- High blood sugar levels (hyperglycemia) – Hyperglycemia is common with TRUQAP and may be severe. Untreated severe hyperglycemia can lead to a condition called diabetic ketoacidosis that can happen in people treated with TRUQAP. Diabetic ketoacidosis is a serious condition that requires treatment in a hospital and that can lead to death. Your healthcare provider will monitor your blood sugar levels before you start and during treatment with TRUQAP. It is not known if TRUQAP is safe in people with type 1 diabetes or people who use insulin to treat their diabetes. Your healthcare provider will monitor your blood sugar levels more often if you have a history of diabetes. Tell your healthcare provider right away if you develop symptoms of hyperglycemia, including excessive thirst, dry mouth, more frequent urination than usual or a bigger amount of urine than normal, blurred vision, increased appetite with weight loss, stomach area (abdominal) pain, unusual tiredness, confusion, nausea, vomiting, fruity odor on breath, dry or flushed skin, difficulty breathing, sleepiness
- Diarrhea – Diarrhea is common during treatment with TRUQAP and may be severe. Severe diarrhea can lead to the loss of too much body water (dehydration). Tell your healthcare provider if you develop any signs of diarrhea, including loose or watery stool. Your healthcare provider will tell you to drink more fluids or take medicines to treat diarrhea
- Skin reactions – Skin reactions are common with TRUQAP and can be severe. Tell your healthcare provider or get medical help right away if you get a new or worsening rash, reddening of the skin, fever, blistering of the lips, eyes or mouth, blisters on the skin, skin peeling, or dry skin
Your healthcare provider may tell you to decrease your dose, temporarily stop your treatment, or completely stop your treatment with TRUQAP if you get certain serious side effects.
The most common side effects of TRUQAP include nausea, tiredness, vomiting, mouth sores and changes in certain blood tests.
These are not all the possible side effects of TRUQAP. Call your healthcare provider for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.
What should I avoid while taking TRUQAP?
- You should not drink grapefruit juice or eat grapefruit during treatment with TRUQAP
What is TRUQAP?
TRUQAP is a prescription oral medicine used in combination with the medicine fulvestrant to treat adults who have hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer that is advanced or that has spread to other parts of the body (metastatic), with an abnormal “PIK3CA”, “AKT1”, or “PTEN” gene, and whose disease has progressed on or after endocrine therapy.
Your healthcare provider will test your cancer for an abnormal “PIK3CA”, “AKT1”, or “PTEN” gene to make sure that TRUQAP is right for you.
It is not known if TRUQAP is safe and effective in children.
Please see full Prescribing Information, including Patient Information for TRUQAP.
You may report side effects related to AstraZeneca products
.
